Hawkins (NASDAQ:HWKN) Rating Lowered to Strong Sell at Zacks Research

Hawkins (NASDAQ:HWKN) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

HWKN has been the subject of several other reports. BWS Financial restated a “buy” rating and issued a $200.00 target price on shares of Hawkins in a report on Monday. Weiss Ratings cut Hawkins from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, July 14th. Finally, Barclays set a $142.00 price target on Hawkins and gave the company an “equal weight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Hawkins currently has an average rating of “Hold” and a consensus target price of $171.00.

Hawkins Trading Up 1.2%

Hawkins stock opened at $135.29 on Tuesday. Hawkins has a one year low of $117.98 and a one year high of $186.15. The company’s fifty day moving average price is $147.18 and its two-hundred day moving average price is $149.48. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.27 and a quick ratio of 1.54. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.54 and a beta of 0.79.

Hawkins (NASDAQ:HWKN) last announced its quarterly earnings results on Wednesday, July 29th. The specialty chemicals company reported $1.35 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.04). The company had revenue of $315.68 million during the quarter, compared to analyst estimates of $313.42 million. Hawkins had a return on equity of 15.42% and a net margin of 7.29%. On average, analysts forecast that Hawkins will post 4.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hawkins

Several large investors have recently made changes to their positions in HWKN. Values First Advisors Inc. lifted its stake in Hawkins by 0.8% in the first quarter. Values First Advisors Inc. now owns 9,855 shares of the specialty chemicals company’s stock valued at $1,514,000 after buying an additional 79 shares in the last quarter. Truist Financial Corp increased its position in shares of Hawkins by 4.7% during the fourth quarter. Truist Financial Corp now owns 1,852 shares of the specialty chemicals company’s stock worth $263,000 after acquiring an additional 83 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Hawkins by 0.6% during the fourth quarter. Farther Finance Advisors LLC now owns 15,090 shares of the specialty chemicals company’s stock worth $2,144,000 after acquiring an additional 88 shares during the period. ProShare Advisors LLC lifted its position in Hawkins by 3.0% in the 4th quarter. ProShare Advisors LLC now owns 3,815 shares of the specialty chemicals company’s stock valued at $542,000 after acquiring an additional 112 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in Hawkins by 0.9% in the 2nd quarter. Quantinno Capital Management LP now owns 13,618 shares of the specialty chemicals company’s stock valued at $1,935,000 after acquiring an additional 124 shares in the last quarter. Institutional investors and hedge funds own 69.71% of the company’s stock.

Trending Headlines about Hawkins

Here are the key news stories impacting Hawkins this week:

• Positive Sentiment: Sidoti raised its Q2 2027 EPS estimate to $1.26 from $1.25, and increased its Q1 2028 forecast to $1.57 from $1.55. The firm also lifted its Q2 2028 estimate to $1.48 from $1.45.
• Neutral Sentiment: Sidoti currently projects FY2027 EPS of $4.20 and FY2028 EPS of $5.00. These forecasts provide a benchmark for future performance, but the estimates remain subject to changes in specialty-chemical demand, pricing and operating costs.
• Negative Sentiment: Sidoti cut its FY2027 EPS estimate to $4.20 from $4.45 and reduced its FY2028 forecast to $5.00 from $5.35. The firm also lowered estimates for Q3 2027 to $0.76 from $0.90, Q4 2027 to $0.82 from $0.95, Q3 2028 to $0.93 from $1.10 and Q4 2028 to $1.02 from $1.25.
• Negative Sentiment: The revisions follow Hawkins’ latest quarterly report, in which EPS of $1.35 missed the $1.39 consensus estimate, although revenue exceeded expectations. With the stock trading below its 50-day and 200-day moving averages and carrying a relatively elevated P/E ratio near 35, downward earnings revisions could limit enthusiasm despite the modest positive quarterly changes.

Hawkins Company Profile

Hawkins, Inc (NASDAQ: HWKN) is a specialty chemical company that produces and distributes water-treatment and industrial chemicals across North America. Founded in 1938 and headquartered in Roseville, Minnesota, the company has built a network of manufacturing facilities and distribution centers that serve municipal, industrial and commercial customers. As a publicly traded entity, Hawkins leverages its long-standing presence in the chemical distribution industry to provide tailored solutions for complex water-treatment challenges and specialty chemical needs.

Hawkins’ product portfolio encompasses a wide range of chemicals, including sodium hypochlorite, sodium hydroxide, hydrogen peroxide, chlorine, acids and specialty blends.